Revance Therapeutics (RVNC) Short Interest Ratio & Short Volume → A new way to collect income from stocks (From DTI) (Ad) Free RVNC Stock Alerts $3.40 +0.11 (+3.34%) (As of 04/26/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Revance Therapeutics Short Interest DataCurrent Short Volume11,630,000 sharesPrevious Short Volume13,550,000 sharesChange Vs. Previous Month-14.17%Dollar Volume Sold Short$46.17 millionShort Interest Ratio / Days to Cover6.5Last Record DateApril 15, 2024Outstanding Shares104,220,000 sharesPercentage of Shares Shorted11.16%Today's Trading Volume2,280,332 sharesAverage Trading Volume1,577,127 sharesToday's Volume Vs. Average145% Short Selling Revance Therapeutics ? Sign up to receive the latest short interest report for Revance Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatRVNC Short Interest Over TimeRVNC Days to Cover Over TimeRVNC Percentage of Float Shorted Over Time Ad DTIIf you have $2,500 bucks… check this out This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! Click here to unlock the Income Glitch training workshop for free. Revance Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202411,630,000 shares $46.17 million -14.2%N/A6.5 $3.97 3/31/202413,550,000 shares $66.67 million +24.7%N/A7.5 $4.92 3/15/202410,870,000 shares $57.67 million -8.5%N/A6.1 $5.31 2/29/202411,880,000 shares $84.82 million -3.7%N/A6.9 $7.14 2/15/202412,340,000 shares $68.86 million -2.5%N/A8.5 $5.58 1/31/202412,650,000 shares $63.63 million -14.6%N/A7.7 $5.03 Get the Latest News and Ratings for RVNC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/202414,810,000 shares $87.97 million +2.9%N/A9 $5.94 12/31/202314,390,000 shares $126.49 million +16.1%N/A8.4 $8.79 12/15/202312,400,000 shares $100.19 million -5.1%N/A7.3 $8.08 11/30/202313,070,000 shares $88.48 million -10.7%N/A6.2 $6.77 11/15/202314,630,000 shares $102.70 million +13.2%N/A7.1 $7.02 10/31/202312,930,000 shares $102.02 million -11.2%N/A6.5 $7.89 10/15/202314,560,000 shares $125.80 million -8.5%N/A7.5 $8.64 9/30/202315,910,000 shares $182.49 million +12.0%N/A8.8 $11.47 9/15/202314,200,000 shares $238.56 million -0.8%N/A7.9 $16.80 8/31/202314,310,000 shares $252.29 million No ChangeN/A10.2 $17.63 8/15/202314,310,000 shares $269.03 million +1.4%N/A10.5 $18.80 7/31/202314,120,000 shares $333.66 million +8.3%N/A10.1 $23.63 7/15/202313,040,000 shares $293.53 million -13.1%N/A10.1 $22.51 6/30/202315,000,000 shares $379.65 million +3.0%N/A11.1 $25.31 6/15/202314,560,000 shares $417.87 million -3.8%N/A11.2 $28.70 5/31/202315,130,000 shares $462.37 million +2.8%N/A11.8 $30.56 5/15/202314,720,000 shares $498.42 million +4.9%N/A10.8 $33.86 4/30/202314,030,000 shares $446.57 million +7.0%N/A11.1 $31.83 4/15/202313,110,000 shares $398.68 million +1.5%N/A10.1 $30.41 3/31/202312,920,000 shares $416.15 million +3.5%N/A8.3 $32.21 3/15/202312,480,000 shares $382.51 million +2.5%N/A7.9 $30.65 2/28/202312,180,000 shares $422.65 million +10.9%N/A7.9 $34.70 2/15/202310,980,000 shares $364.65 million -4.7%N/A7.5 $33.21 1/31/202311,520,000 shares $399.51 million -12.6%N/A7.6 $34.68 1/15/202313,180,000 shares $367.99 million +0.9%N/A8.7 $27.92 12/30/202213,060,000 shares $241.09 million +29.4%N/A9 $18.46 12/15/202210,090,000 shares $216.94 million -0.1%N/A7.9 $21.50 11/30/202210,100,000 shares $219.27 million -1.4%N/A6.6 $21.71 11/15/202210,240,000 shares $243.30 million +7.1%N/A6.2 $23.76 10/31/20229,560,000 shares $213.28 million +0.4%14.0%6 $22.31 10/15/20229,520,000 shares $238.95 million +1.6%13.9%6.4 $25.10 9/30/20229,370,000 shares $252.99 million +16.5%13.8%7 $27.00 9/15/20228,040,000 shares $212.34 million +3.7%11.8%6.9 $26.41 8/31/20227,750,000 shares $154.23 million -4.2%11.4%8.1 $19.90If you have $2,500 bucks… check this out (Ad)This computer whiz has been averaging 234% per year with an undefeated strategy he calls… The “Income Glitch” And he’s been making out like a bandit with a 100% success rate on over 64 trade opportunities! Click here to unlock the Income Glitch training workshop for free. RVNC Short Interest - Frequently Asked Questions What is Revance Therapeutics' current short interest? Short interest is the volume of Revance Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 15th, traders have sold 11,630,000 shares of RVNC short. Learn More on Revance Therapeutics' current short interest. What is a good short interest ratio for Revance Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. RVNC shares currently have a short interest ratio of 6.0. Learn More on Revance Therapeutics's short interest ratio. Which institutional investors are shorting Revance Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Revance Therapeutics: Simplex Trading LLC, and Wolverine Asset Management LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Revance Therapeutics' short interest increasing or decreasing? Revance Therapeutics saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 11,630,000 shares, a drop of 14.2% from the previous total of 13,550,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Revance Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Revance Therapeutics: PepGen Inc. (1.25%), Nkarta, Inc. (11.27%), Heron Therapeutics, Inc. (16.92%), Mersana Therapeutics, Inc. (8.72%), Nature's Sunshine Products, Inc. (0.63%), Organogenesis Holdings Inc. (10.76%), Biomea Fusion, Inc. (49.86%), Esperion Therapeutics, Inc. (11.04%), Corbus Pharmaceuticals Holdings, Inc. (6.00%), Harrow Health, Inc. (16.74%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Revance Therapeutics stock? Short selling RVNC is an investing strategy that aims to generate trading profit from Revance Therapeutics as its price is falling. RVNC shares are trading up $0.11 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Revance Therapeutics? A short squeeze for Revance Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of RVNC, which in turn drives the price of the stock up even further. How often is Revance Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RVNC, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: PepGen Short Interest Data Nkarta Short Interest Data Heron Therapeutics Short Interest Data Mersana Therapeutics Short Interest Data Nature's Sunshine Products Short Interest Data Organogenesis Short Interest Data Biomea Fusion Short Interest Data Esperion Therapeutics Short Interest Data Corbus Pharmaceuticals Short Interest Data Harrow Health Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:RVNC) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press